Takeda said in September 2024 that it received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg, a selective oral inhibitor of ...

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

The ALISCA-Breast1 study is investigating alisertib in combination with endocrine therapy for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative ...

There are approx. 80+ key companies which are developing the therapies for Dementia Associated With Alzheimer's Disease. The companies which have their Dementia Associated With Alzheimer's Disease ...

Breast cancer is classified into several subtypes depending on the presence or absence of the patient's factors.

US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer: Dublin Friday, November 22, 2024, 1 ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

Australian women have been raving about a 'beautiful' anti-ageing skincare serum that transforms their skin, with many swearing they 'won't use anything else.' ...

So, I’m mildly freaking out,” Margaret Lawson wrote from St Andrew’s Hospital where, having not been able to get an appointment with a GP, she’d gone to ask for a CT scan for a lingering headache.

The global benign prostatic hyperplasia (BPH) prostate treatment market is set for consistent growth, with its valuation ...